Genprex Collaborates with University of Michigan for Innovative Cancer Research
Genprex, Inc. (NASDAQ: GNPX) is thrilled to announce its new Sponsored Research Agreement (SRA) with the University of Michigan Rogel Cancer Center. This partnership aims to explore the therapeutic potential of TUSC2 combined with ALK-inhibitors for treating ALK-positive lung cancer, particularly focusing on its lead drug candidate, Reqorsa® Gene Therapy.
Unveiling the Research Focus
The collaborative research seeks to investigate the effects of TUSC2, a tumor suppressor gene, when used alongside ALK-inhibitors in patients with ALK-EML4 positive translocated lung cancer. This study is particularly significant for patients who are in need of more effective treatment options.
Expanding Horizons Through Collaboration
Alongside the University of Michigan, Genprex has teamed up with ALK Positive, a patient-focused non-profit organization dedicated to enhancing the lives of individuals battling ALK-positive lung cancer. This strategic collaboration showcases a commitment to advancing therapeutic solutions and improving patient outcomes in a treatment area that has great unmet needs.
The Promise of Reqorsa® Gene Therapy
Reqorsa® Gene Therapy aims to deliver the TUSC2 gene directly into cancer cells, offering a unique mechanism to counteract the malignant growth associated with lung cancer. Research has indicated that a significant percentage of non-small cell lung cancer (NSCLC) cases exhibit reduced TUSC2 protein levels, highlighting the critical role this gene plays in tumor suppression.
Groundbreaking Preclinical Findings
Recently, collaborative researchers at the Rogel Cancer Center presented encouraging preclinical results indicating that Reqorsa® effectively induced apoptosis in lung cancer cell lines resistant to alectinib, an established ALK-inhibitor. These findings support the potential of Reqorsa® as a promising treatment strategy against resistant lung cancer forms.
Addressing a Significant Need
ALK-positive lung cancer primarily affects younger individuals. While existing ALK-targeted therapies have proven beneficial, resistance to these treatments can develop over time. The five-year survival rate for patients with ALK-EML4 translocated lung cancer stands at approximately 40.9%. This statistic underscores the need for innovative therapies like Reqorsa® to enhance survival chances.
About Reqorsa® Gene Therapy
Recognizing the need for novel therapies, Genopexx’s Reqorsa® Gene Therapy utilizes a groundbreaking system that encapsulates the TUSC2 gene within non-viral nanoparticles. Designed to deliver genes directly to cancer cells efficiently, this treatment reduces the unwanted uptake by healthy tissue, maximizing its effectiveness against the tumor.
Genprex's Vision for the Future
Genprex envisions that when combined with currently approved therapies, Reqorsa® could transform the treatment landscape for lung cancer patients. The company’s ongoing commitment to research and collaboration positions it to innovate in the therapeutic domain effectively, ultimately benefiting those with limited treatment options.
Frequently Asked Questions
1. What is the purpose of the Genprex and University of Michigan collaboration?
The collaboration aims to study the effectiveness of TUSC2 combined with ALK-inhibitors for treating ALK-positive lung cancer.
2. What is Reqorsa® Gene Therapy?
Reqorsa® Gene Therapy is a treatment that delivers the TUSC2 gene to cancer cells, potentially enhancing tumor suppression effects.
3. Why is there a need for this research?
Current therapies for ALK-positive lung cancer can become ineffective due to resistance, highlighting the need for new treatment options.
4. How does TUSC2 relate to lung cancer?
TUSC2 is a tumor suppressor gene often found to be mutated or deleted in various forms of lung cancer.
5. What is the significance of the preclinical findings?
The findings indicate that Reqorsa® may help overcome resistance to typical treatments and enhance patient survival rates.
